What are the contraindications to using Kenalog (triamcinolone acetonide)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Contraindications to Kenalog (Triamcinolone Acetonide) Use

Kenalog is absolutely contraindicated in patients with hypersensitivity to triamcinolone acetonide or any component of the formulation, and intramuscular preparations are contraindicated for idiopathic thrombocytopenic purpura. 1

Absolute Contraindications

Hypersensitivity Reactions

  • Do not use in patients with known hypersensitivity to triamcinolone acetonide or any formulation components 2, 1
  • IgE-mediated anaphylaxis has been documented, even after years of uneventful use, presenting with urticaria, hypotension, and facial numbness within 15-20 minutes of injection 3
  • Patients with previous allergic reactions to triamcinolone should be offered alternative corticosteroids after appropriate skin testing 3

Hematologic Contraindication

  • Intramuscular corticosteroid preparations are absolutely contraindicated for idiopathic thrombocytopenic purpura 1

Relative Contraindications and High-Risk Situations

Active Infections

  • Avoid injection at sites with active skin infections including impetigo or herpes 4
  • Exercise caution with large injections in patients with active tuberculosis or systemic fungal infections 4
  • Patients with HIV may absorb steroids at higher rates and require additional monitoring 2

Pregnancy and Lactation

  • All weight-loss medications containing corticosteroids are contraindicated in women who are pregnant or actively trying to conceive 5
  • Women of reproductive potential require counseling about reliable contraception methods 5

Cardiovascular and Metabolic Conditions

  • Use with caution in patients with uncontrolled diabetes, heart failure, or severe hypertension 4
  • Monitor blood pressure regularly during treatment 2

Critical Clinical Pitfalls

Injection Site Selection

  • Never inject into areas with lipohypertrophy, inflammation, edema, ulceration, or active infection 4
  • Facial and intertriginous areas carry higher risk for adverse effects including atrophy and telangiectasia 4

Systemic Absorption Risks

  • Repeated injections can suppress the hypothalamic-pituitary-adrenal axis, particularly with higher doses or prolonged use 4, 2
  • Monitor for growth suppression in children receiving long-term therapy 2
  • Consider ophthalmologic examination for patients on chronic therapy due to posterior subcapsular cataract risk 2

Post-Injection Complications

  • Severe postinjection flares can mimic septic arthritis with acute onset of intense pain, swelling, and inability to ambulate within 2 hours of injection 6
  • This represents an acute crystal-induced inflammatory response to triamcinolone acetonide crystals, confirmed by polarized light microscopy of synovial fluid 6
  • Although rare, inform patients of this potential severe reaction before administration 6

Special Population Considerations

Pediatric Patients

  • Growth velocity must be tracked in children receiving long-term administration 2
  • Hypothalamic-pituitary-adrenal axis suppression monitoring is essential 2

Patients with Multiple Comorbidities

  • Evaluate for glucose intolerance and decreased bone density with chronic use 2
  • Consider alternative therapies when NSAID contraindications exist, as intramuscular triamcinolone may be a reasonable option for conditions like pseudogout 7

References

Guideline

Corticosteroid Usage and Dosage Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Local Injectable Steroids: Recommended Dosing and Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Extreme Postinjection Flare in Response to Intra-Articular Triamcinolone Acetonide (Kenalog).

American journal of orthopedics (Belle Mead, N.J.), 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.